TrialNeuro-oncology2025

Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trial.

Karsten Nysom et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.